Can I Take St. John's Wort with Spironolactone?

The short answer: avoid this combination

No, you should not take St. John's Wort (Hypericum perforatum) while you are on spironolactone without explicit guidance from your prescriber. The supplement is one of the most potent over-the-counter inducers of the liver enzyme CYP3A4, and spironolactone is metabolized substantially through CYP3A4 and related pathways. When CYP3A4 is induced, spironolactone is cleared faster, blood levels drop, and the drug may no longer work as well as it should.

This matters most if you are taking spironolactone for PCOS-related hyperandrogenism, hirsutism, or hormonal acne. Those indications depend on a sustained plasma concentration of spironolactone and its active metabolite canrenone to block androgen receptors at the follicle and adrenal level. A meaningful drop in drug exposure can let androgens reassert themselves, meaning acne flares, facial hair growth, or cycle irregularity can return even though you are still filling your prescription.

What is St. John's Wort, and why do women reach for it?

St. John's Wort is an herbal extract sold without a prescription for low-to-moderate depression, anxiety, and premenstrual mood symptoms. A 2008 Cochrane review of 29 trials found St. John's Wort significantly more effective than placebo for mild-to-moderate depression, which is why so many women try it before or instead of a prescription antidepressant.

Women are more likely than men to experience depression across the reproductive lifespan, and women with PCOS carry a particularly elevated risk. A meta-analysis in Human Reproduction found that women with PCOS have roughly a three-fold higher prevalence of depression compared to women without PCOS. So the overlap between "woman on spironolactone for PCOS" and "woman considering St. John's Wort for mood" is real and clinically relevant.

Why the appeal does not outweigh the risk here

St. John's Wort feels safe because it is natural and sold freely in pharmacies. In reality, it carries more documented drug interactions than almost any other supplement available without a prescription. The FDA issued a public health advisory in 2000 specifically warning that St. John's Wort induces CYP3A4 and P-glycoprotein and can cause clinically significant reductions in the plasma concentrations of multiple drugs. The agency first flagged the interaction with indinavir, cyclosporine, and anticoagulants, but the mechanism applies broadly to any CYP3A4-cleared medication.

The pharmacokinetic mechanism: how St. John's Wort affects spironolactone levels

This interaction is pharmacokinetic, not pharmacodynamic. St. John's Wort does not oppose spironolactone's mechanism of action at the androgen receptor or the mineralocorticoid receptor. Instead, it speeds up the enzyme machinery that breaks spironolactone down before it can reach those receptors.

CYP3A4 induction explained simply

CYP3A4 is an enzyme in the liver and intestinal wall that metabolizes roughly 50% of all prescription drugs. The active constituent of St. John's Wort, hyperforin, activates the pregnane X receptor (PXR), which then transcribes more CYP3A4 and P-glycoprotein. More enzyme means faster breakdown of any substrate that uses that pathway.

Induction is not immediate. It builds over days. CYP3A4 induction from St. John's Wort typically reaches clinically measurable levels within 3 to 7 days of daily use, and it persists for approximately two weeks after you stop the supplement because the newly synthesized enzyme protein takes time to degrade.

Spironolactone's metabolic pathway

Spironolactone is a prodrug. After oral absorption, it is rapidly converted to several active metabolites, the most important being canrenone and 7-alpha-thiomethylspironolactone. Spironolactone and canrenone are both substrates of CYP3A4. P-glycoprotein (P-gp) at the intestinal wall also limits how much spironolactone enters systemic circulation in the first place. St. John's Wort induces both CYP3A4 and P-gp simultaneously, creating a dual mechanism for reducing drug exposure: less drug gets in, and what does get in is cleared faster.

How much does drug exposure drop?

No clinical pharmacokinetic study has measured spironolactone plasma levels specifically in women taking St. John's Wort simultaneously. This is an important evidence gap, and you deserve to know that the magnitude of the interaction is extrapolated from what St. John's Wort does to other CYP3A4 substrates.

A landmark study in The Lancet by Piscitelli et al. (2000) showed that St. John's Wort reduced the AUC of indinavir, another CYP3A4 substrate, by 57% and reduced the Cmax by 32%. A study in healthy volunteers showed St. John's Wort reduced cyclosporine blood levels by approximately 49%. Spironolactone's CYP3A4 dependence is moderate rather than complete, so the magnitude of reduction in its case is likely smaller than these examples, but even a 20-30% drop in active drug exposure may be enough to blunt the androgen-blocking effect you are relying on.

A practical way to think about this: spironolactone's therapeutic effect for acne and hirsutism is dose-dependent and concentration-dependent. Women are commonly prescribed 50 to 200 mg daily for these indications. If St. John's Wort effectively reduces your circulating drug exposure by even a moderate fraction, you may functionally be getting the equivalent of a meaningfully lower dose without anyone knowing, because spironolactone levels are not routinely monitored by serum testing in clinical practice for dermatological or PCOS indications.

Which women are most affected?

Women using spironolactone for PCOS

PCOS affects approximately 8-13% of women of reproductive age worldwide. Hyperandrogenism, the excess androgen activity driving acne, hirsutism, and scalp hair thinning, is the mechanism spironolactone targets. For PCOS treatment, doses typically range from 100 to 200 mg daily, and the drug requires several months of consistent exposure before clinical improvement is visible. Losing drug efficacy partway through because of an unrecognized supplement interaction delays that outcome.

Women using spironolactone for hormonal acne

Spironolactone at 50 to 150 mg daily is now widely used off-label for hormonal acne in adult women. A randomized controlled trial published in the British Journal of Dermatology confirmed spironolactone significantly reduced acne lesion counts versus placebo in women aged 18 to 45. If St. John's Wort lowers effective exposure, acne may return, and that is often misattributed to the drug "not working anymore" rather than to the supplement.

Women using spironolactone for hirsutism

Clinical improvement in hirsutism is slow with any anti-androgen treatment. Visible hair reduction typically takes 6 to 12 months. Any factor that blunts drug efficacy during that window extends an already long treatment timeline.

Perimenopausal and postmenopausal women

Spironolactone is occasionally used off-label in perimenopausal women for late-onset acne or as a component of PCOS management when hormonal therapy is not appropriate. Mood changes are also common in perimenopause, making St. John's Wort tempting. If you are in this life stage and on spironolactone, the same CYP3A4 interaction applies. Perimenopausal physiology does alter drug metabolism generally because of fluctuating estrogen's effects on CYP enzyme expression, though this has not been specifically studied for this drug pair.

Pregnancy, lactation, and contraception: what every woman on spironolactone must know

Spironolactone is contraindicated in pregnancy. This is not a theoretical concern. Spironolactone has anti-androgenic properties that could interfere with normal male fetal genital development. Animal studies show feminization of male fetuses at doses relevant to human use, and while direct human teratogenicity data are limited because prescribers appropriately avoid the drug in pregnancy, ACOG and dermatology guidelines recommend that spironolactone be used only with reliable contraception in women of reproductive age. Most prescribers require an established, reliable contraceptive method before starting or continuing spironolactone in premenopausal women.

St. John's Wort adds another contraception concern. St. John's Wort reduces the plasma concentrations of ethinyl estradiol and norethindrone in combined oral contraceptives, potentially reducing contraceptive efficacy. If you are taking a combined oral contraceptive as your method of contraception while on spironolactone, adding St. John's Wort may simultaneously undermine your contraception and your acne or PCOS treatment.

Lactation: Spironolactone passes into breast milk in small amounts. Current data suggest the relative infant dose is low, approximately 0.2% of the weight-adjusted maternal dose, and most lactation-medicine specialists consider short-term use compatible with breastfeeding at the doses used for acne and PCOS, though this should be an individualized decision with your prescriber. St. John's Wort in lactation is poorly studied, and the LactMed database notes insufficient data to recommend its use during breastfeeding.

Trying to conceive: If you are actively trying to conceive, spironolactone should be discontinued at least one menstrual cycle before conception attempts because of the teratogenicity concern. Do not combine it with St. John's Wort during this window. Discuss transition plans with your prescriber well before you start trying.

What to do if you are already taking both

First, do not stop spironolactone abruptly without talking to your prescriber. Sudden discontinuation may cause rebound androgen effects, including acne flare or worsening hirsutism.

Second, tell your prescriber and pharmacist exactly what you are taking, including dose and how long you have been combining the two. Some clinicians may order a blood pressure check and potassium level regardless, since spironolactone also acts as a potassium-sparing diuretic.

Third, St. John's Wort can typically be tapered down and stopped over one to two weeks. CYP3A4 induction from St. John's Wort resolves over approximately 14 days after discontinuation, so spironolactone levels should normalize within that window.

Fourth, if mood support is genuinely needed, see the section below on alternatives before restarting St. John's Wort.

Safer mood-support options to consider with spironolactone

Several options carry no clinically significant CYP3A4 interaction and may be appropriate depending on your health history.

Prescription alternatives

SSRIs such as sertraline and escitalopram are not CYP3A4 inducers. They are metabolized primarily via CYP2C19 and CYP2D6. The American College of Obstetricians and Gynecologists supports SSRIs as first-line pharmacotherapy for premenstrual dysphoric disorder and moderate-to-severe depression. If your mood symptoms are significant, an SSRI alongside spironolactone is pharmacologically compatible.

Bupropion uses CYP2B6 for its own metabolism and is an inhibitor (not inducer) of CYP2D6. It does not induce CYP3A4, making it a reasonable option to discuss with your prescriber if SSRI side effects have been a barrier.

Non-pharmacological options with reasonable evidence

Magnesium glycinate at 250 to 400 mg daily has preliminary evidence for premenstrual mood and anxiety without any meaningful drug interaction concern. A 2017 review in Nutrients found magnesium supplementation associated with reduced anxiety in mild-to-moderate anxiety states. Magnesium has no known CYP enzyme interaction.

Cognitive behavioral therapy (CBT) has strong evidence for mild-to-moderate depression, comparable in many trials to antidepressant pharmacotherapy, and carries zero drug interaction risk.

SAMe (S-adenosylmethionine) is sometimes used for mild depression. It does not induce CYP3A4, though its evidence base is less strong than SSRIs or St. John's Wort, and it should be avoided in bipolar disorder.

Note on evidence gap: The absence of a clinical pharmacokinetic trial directly measuring the spironolactone-St. John's Wort interaction means precise guidance on magnitude of effect cannot be given. What is known is the mechanism, and the mechanism is well-characterized enough to justify avoiding the combination until direct data exist.

Monitoring and what to watch for

If you were taking both and have now stopped St. John's Wort, watch for:

• A return of acne or hirsutism worsening over the first few weeks (suggests drug levels were meaningfully suppressed and are now recovering).
• Blood pressure changes. Spironolactone lowers blood pressure in some women, and as levels normalize after stopping the inducer, blood pressure effects may become more prominent.
• Potassium. Spironolactone can raise serum potassium, particularly in women with kidney disease or who also take ACE inhibitors, ARBs, or NSAIDs. Stopping an inducer effectively increases your drug exposure, so your prescriber may want to recheck potassium if you are in a higher-risk category.

For most healthy women at standard spironolactone doses for acne or PCOS, rebound hyperkalemia from stopping St. John's Wort is unlikely but not impossible. Reporting any muscle weakness, palpitations, or unusual fatigue to your prescriber is reasonable.

Who spironolactone is right for, and who should be cautious

Good candidates

Women of reproductive age with confirmed or suspected androgen-excess conditions including PCOS-driven hirsutism, adult hormonal acne that has not responded to topical treatments, and female-pattern hair loss with an androgenic component. Women who are using reliable hormonal or long-acting reversible contraception. Perimenopausal women with late-onset acne when hormonal therapy is not preferred.

Candidates who need extra caution or individualized assessment

Women with impaired kidney function, because spironolactone's potassium-sparing effect carries more risk in renal insufficiency. Women with adrenal insufficiency. Women who are pregnant or planning pregnancy in the near term. Women taking multiple medications that already affect CYP3A4 or potassium balance. Women taking lithium, since spironolactone can alter lithium clearance.

If you fall into any of these categories and are also considering St. John's Wort, the case for avoiding that supplement becomes even clearer.

A note on what we do not yet know

Direct pharmacokinetic data on the spironolactone-St. John's Wort interaction in women specifically does not exist in the published literature as of this writing. Women have historically been underrepresented in drug-interaction pharmacokinetic trials, and herbal-drug interaction studies are even less likely to be sex-stratified. The interaction described here is mechanistically sound and supported by St. John's Wort's behavior with similar CYP3A4 substrates, but the precise effect on spironolactone bioavailability in a 28-year-old woman with PCOS taking 100 mg daily has not been measured in a controlled trial. Your prescriber should know this limitation when you discuss it, and that honesty is more useful to you than false precision.